Insider Buying Stocks
ENOV is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
ENOVIS CORP (ENOV) Stock Price & Overview
NYSE:ENOV • US1940141062
Current stock price
24.1 USD
+1.29 (+5.66%)
At close:
24.1 USD
0 (0%)
After Hours:
The current stock price of ENOV is 24.1 USD. Today ENOV is up by 5.66%. In the past month the price increased by 3.12%. In the past year, price decreased by -31.34%.
ENOV Key Statistics
52-Week Range21 - 37.85
Current ENOV stock price positioned within its 52-week range.
1-Month Range21.48 - 27.04
Current ENOV stock price positioned within its 1-month range.
- Market Cap
- 1.387B
- P/E
- 7.30
- Fwd P/E
- 6.52
- EPS (TTM)
- 3.30
- Dividend Yield
- N/A
ENOV Stock Performance
Today
+5.66%
1 Week
-8.43%
1 Month
+3.12%
3 Months
+4.74%
Longer-term
6 Months -26.68%
1 Year -31.34%
2 Years -56.36%
3 Years -58.63%
5 Years N/A
10 Years N/A
ENOV Stock Chart
ENOV Stock Screens
ENOV currently appears in the following ChartMill screener lists.
ENOV Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ENOV. When comparing the yearly performance of all stocks, ENOV is a bad performer in the overall market: 81.92% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ENOV Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ENOV. While ENOV is still in line with the averages on profitability rating, there are concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ENOV Earnings
On February 26, 2026 ENOV reported an EPS of 0.95 and a revenue of 575.76M. The company beat EPS expectations (13.32% surprise) and missed revenue expectations (-3.32% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.95
Revenue Reported575.758M
EPS Surprise 13.32%
Revenue Surprise -3.32%
ENOV Forecast & Estimates
18 analysts have analysed ENOV and the average price target is 46.09 USD. This implies a price increase of 91.23% is expected in the next year compared to the current price of 24.1.
For the next year, analysts expect an EPS growth of 11.93% and a revenue growth 3.91% for ENOV
Analysts
Analysts84.44
Price Target46.09 (91.24%)
EPS Next Y11.93%
Revenue Next Year3.91%
ENOV Groups
Sector & Classification
Sector
Health Care Sub-Industry
Health Care Equipment ENOV Financial Highlights
Over the last trailing twelve months ENOV reported a non-GAAP Earnings per Share(EPS) of 3.3. The EPS increased by 16.61% compared to the year before.
Income Statements
Revenue(TTM)2.25B
Net Income(TTM)-1.18B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.89% | ||
| ROE | -79.51% | ||
| Debt/Equity | 0.85 |
Chartmill High Growth Momentum
EPS Q2Q%-3.06%
Sales Q2Q%2.64%
EPS 1Y (TTM)16.61%
Revenue 1Y (TTM)6.66%
ENOV Ownership
Ownership
Inst Owners118.02%
Shares57.54M
Float56.66M
Ins Owners1.72%
Short Float %14.56%
Short Ratio8.12
ENOV Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 41.34 | 170.062B | ||
| ABT | ABBOTT LABORATORIES | 14.5 | 160.7B | ||
| SYK | STRYKER CORP | 21.66 | 126.249B | ||
| BSX | BOSTON SCIENTIFIC CORP | 15.72 | 97.627B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.95 | 45.962B | ||
| IDXX | IDEXX LABORATORIES INC | 38.22 | 44.549B | ||
| BDX | BECTON DICKINSON AND CO | 11.15 | 44.092B | ||
| RMD | RESMED INC | 17.91 | 31.978B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.32 | 31.89B | ||
| DXCM | DEXCOM INC | 24.21 | 24.131B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.76 | 17.894B | ||
| PODD | INSULET CORP | 29.24 | 13.313B | ||
| PEN | PENUMBRA INC | 64.72 | 13.094B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENOV
Company Profile
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,802 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Company Info
IPO: 2008-05-08
ENOVIS CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE US
Employees: 7802
Phone: 13022529160
ENOVIS CORP / ENOV FAQ
What does ENOVIS CORP do?
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,802 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
What is the stock price of ENOVIS CORP today?
The current stock price of ENOV is 24.1 USD. The price increased by 5.66% in the last trading session.
Does ENOV stock pay dividends?
ENOV does not pay a dividend.
What is the ChartMill rating of ENOVIS CORP stock?
ENOV has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is ENOVIS CORP (ENOV) stock traded?
ENOV stock is listed on the New York Stock Exchange exchange.
How is the valuation of ENOVIS CORP (ENOV) based on its PE ratio?
The PE ratio for ENOVIS CORP (ENOV) is 7.3. This is based on the reported non-GAAP earnings per share of 3.3 and the current share price of 24.1 USD.